> The Texas House handed the state governor a lopsided defeat yesterday, rejecting his order that required HPV vaccines as a condition for school attendance. Report
> The FDA is demanding drug makers to add new warnings to sleep drugs to alert users about two rare but dangerous side effects: sleep-driving and severe allergic reactions. Report
> Prima BioMed announced that a small Phase IIa trial for its ovarian cancer therapy "exceeded expectations." Four of 21 patients in the study had either a positive response or saw the disease stabilize, exceeding the 15 percent response rate that researchers had set as a goal. Report
> Optimer Pharmaceuticals reported that the FDA has agreed with the recommendation of the independent data safety monitoring board to advance Difimicin (OPT-80/PAR101) into Phase III clinical studies. Release
> India's Syngene International has inked an R&D and early drug development agreement with Bristol-Myers Squibb. No terms were disclosed. Report
> Advanced Life Sciences Holdings anthrax inhalation therapy cethromycin has received orphan drug status. Report
> The FDA has given Avigen the green light to commence Phase II clinical development of AV650 (tolperisone). Release
And Finally… A new study projects a looming shortage of cancer doctors as demand for their services soars. Article